1 / 20

Timothy Mills, Ph.D., Managing Director Sanderling Ventures

Investing in BioMedical Start-ups at The University of Colorado Venture Capital Financing of University-Based Start-up Companies. Timothy Mills, Ph.D., Managing Director Sanderling Ventures. Dave Drake Director of Business Development CU Tech Transfer Office. The Venture Capital Landscape.

spike
Download Presentation

Timothy Mills, Ph.D., Managing Director Sanderling Ventures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Investing in BioMedical Start-ups at The University of ColoradoVenture Capital Financing of University-Based Start-up Companies Timothy Mills, Ph.D., Managing Director Sanderling Ventures Dave Drake Director of Business Development CU Tech Transfer Office

  2. The Venture Capital Landscape • Venture funds focused on life science investments differ widely in their investment approach • Stage of Investment • Size of fund and hence size of target investment amount • Area(s) of investment focus • Sanderling Venture’s Approach

  3. The Venture Capital Landscape • Venture funds have a finite life cycle, which determines their receptivity to new investment opportunities • Early stage venture funds must “swing for the fence” on each investment, unlike angel investors or corporate investors/licensees

  4. Venture Mathematics • A successful venture fund must earn a compounded, cash-on-cash gross return in excess of 30% over its ten year term (22.5% net return) • The typical fund will be fully invested after 2-3 years • The analysis of valuation is driven by multiples (between 5x and 10x)

  5. As a result, valuation is determined by reference to: • Amount of money to be raised, which is determined based on the funds needed to achieve the next set of milestones • Likely “pre-money” valuation of the next round, based on the step-up in valuation expected to be created by applying the proceeds raised in the current round of financing • The number of subsequent financing rounds required until liquidity (IPO or sale), and the funds likely to be raised in each round • Comparables are of limited utility – Each deal is unique

  6. What VCs are Looking forProducts • A novel biological or chemical hypothesis • A well understood mechanism of action • Proof of principle • Significant unmet need • A strong IP position (both freedom to operate and power to exclude) • A strategy for partnering so that the risks associated with the timing of FDA approval can be passed on to someone else (although clear clinical endpoints are a plus)

  7. What VCs are Looking forTools • Reducing the failure rate and/or increasing the efficiency of drug discovery or development • A technology that provides useful information which addresses an unmet need • A strategy for partnering/sales which takes account of the sales cycle and the need to differentiate oneself amidst the background noise, confusion, and competition

  8. Start-Up PitfallsVenture Capital Nightmares • Undocumented commitments to co-founders or promoters who assist in arranging the initial round of financing • Unconventional corporate or capital structures • Equity arrangements that are not tied to future performance of services; everyone must have “skin in the game” • A management team lacking a critical skill set • An unwieldy or dysfunctional board of directors

  9. Intellectual Property Pitfalls • All of the investors/institutions have not assigned their rights to the university • The university has not made patent filings on a timely basis in relevant markets for the technology • The technology’s inventors published their ideas prior to the filing of patent applications • The claims of the filed patent applications are not broad enough to cover the intended application of the technology • A non-infringement analysis (freedom to operate) has not been done

  10. Intellectual Property PitfallsWhy is this so important? • Because universities typically provide • No representations or warranties • No indemnification • An “as is” transfer of rights to the underlying intellectual property • This translates to increased RISK for the venture investor

  11. Other IP Diligence Traps • The original sponsor of the research retains “strings” restricting its commercialization • The new company requires access to biological materials, information, or other technologies not covered by the license • Only patents and tangible property can be licensed, not “know how” • The inventor’s activities are limited by pre-existing, third party consulting agreements

  12. Licensing Pitfalls • Technology licensing arrangements that fail to contemplate the most likely business model and liquidity event • Failure to study the university’s income-sharing and conflict of interest policies • Failure to adequately and appropriately incentivize the inventors/scientific founders • Inability to have input on patent prosecution and intellectual property strategy for licensed technology

  13. Key Licensing Termsthe economics • Royalty (typically on Net Sales) • How is it calculated? What is included/excluded? • Sublicense Royalty • Why so much higher than the Net Sales Royalty? • Equity • Who will manage the equity and what rights accompany the equity? • Minimum Annual or Minimum Royalty Payments • Do these change? How? Will they be reduced if patents don’t issue, certain claims are rejected, or generic competitors emerge? • Sponsored Research • Part of the deal?

  14. Key Licensing Termsnon-economics • Scope of license • Field of Use restrictions • Exclusive/Non-Exclusive • Geographic limitations • Royalty anti-stacking provisions • Conditions put upon sublicensing • Sublicensee rules and restrictions • What if primary licensee breaches license? • Assignability in the event of a corporate change of control

  15. Price Dividend Provisions Liquidation Preferences Redemption Conversion Automatic Conversion Anti-Dilution Provisions Voting Rights Protective Provisions Pay to Play Provisions Board Rights and Composition Information Rights Registration Rights Right of First Offer Right of First Refusal Co-Sale Rights Drag-along Rights Stock Restriction Agreements Deal StructureThe Term Sheet

  16. Deal StructureThe Term Sheet • Employee Agreements • Indemnification Agreement • For Directors and affiliated entities • Legal Fees and Expenses • Conditions Precedent • Full and complete disclosure and due diligence • Negotiations • Exclusivity Period • Confidentiality • Status • Governing Law

  17. A “typical” Deal Structure Post-Series A First Round Financing • University of Colorado • 1-15% • Management/ Board/Employee pool • 15-25% • Founders/Seed Investors • 15-25% • Venture Funds • Remaining unallocated amount

  18. Deal Structure –VC Headaches • Disproportionate equity to the founders with no vesting requirement • Equity to people who don’t contribute value • Unwieldy “Dilution protection” provisions • Valuations at pre-venture rounds that are too high and set unrealistic expectations • Unnecessary, complex, “finders fee” expectations by pre-venture placement agents • Any previously-agreed to structure that imposes unpalatable conditions on future financings or deals down the road

  19. Building for a Successful Venture Capital Financing • Choose the right fund to lead the deal • Choose the right people to run the company • Anticipate and resolve in advance potential “deal killers” • Make sure there’s enough cash runway • Clearly understand and be able to articulate the business model • Divide the equity in a sensible manner

  20. Biotechnology and Therapeutics Biotechnology & Therapeutics Drug Discovery Tools Genomics Medical Devices and Instrumentation Medical Devices and Instrumentation Biologic Devices Drug Delivery Medical Imaging i-Health Healthcare Delivery Medical Information Technology Sanderling Investment Focus

More Related